Pardes Biosciences, Inc. (PRDS): Price and Financial Metrics
PRDS Price/Volume Stats
Current price | $2.16 | 52-week high | $3.93 |
Prev. close | $2.16 | 52-week low | $0.75 |
Day low | $2.13 | Volume | 2,378,900 |
Day high | $2.20 | Avg. volume | 359,530 |
50-day MA | $2.03 | Dividend yield | N/A |
200-day MA | $1.70 | Market Cap | 133.95M |
PRDS Stock Price Chart Interactive Chart >
Pardes Biosciences, Inc. (PRDS) Company Bio
Pardes Biosciences, Inc., a pre-clinical stage biotechnology company, engages in developing oral direct acting antivirals. Its antivirals target viral main cysteine protease, an essential viral protein required for coronaviruses to replicate. Pardes Biosciences, Inc. was incorporated in 2020 and is based in Carlsbad, California.
Latest PRDS News From Around the Web
Below are the latest news stories about PARDES BIOSCIENCES INC that investors may wish to consider to help them evaluate PRDS as an investment opportunity.
Pardes Biosciences Announces Closing of Tender OfferCARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes’ outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent |
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesLARKSPUR, Calif., August 28, 2023--As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (Nasdaq: PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the "CVR") associa |
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesLARKSPUR, Calif., August 17, 2023--As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (Nasdaq: PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more |
Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsCARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company’s net cash at closing, plus a non-tradeable contingent value right (the CVR) associated wi |
Pardes Biosciences Reports First Quarter 2023 Financial ResultsCARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023. “As previously announced this year, Pardes Biosciences has initiated a process to evaluate strategic alternatives to maximize shareholder value that may potentially result in changes to our business strategy,” said Thomas G. Wiggans, Chief Executive Officer and Chair of Pardes Biosciences. First Quarter 2023 Financial Results Pard |
PRDS Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | 11.34% |
3-year | -78.72% |
5-year | N/A |
YTD | N/A |
2023 | 0.00% |
2022 | -89.68% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...